prikaz prve stranice dokumenta Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients
Medical Hypotheses, 82 (2014), 2; 205-208. https://doi.org/10.1016/j.mehy.2013.11.039
Mikolašević, Ivana; Rački, Sanjin; Zaputović, Luka.; Lukenda, V.; Milić, Sandra; Orlić, Lidija

Cite this document

Mikolašević, I., Rački, S., Zaputović, L., Lukenda, V., Milić, S. & Orlić, L. (2014). Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients. Medical Hypotheses, 82. (2), 205-208. doi: 10.1016/j.mehy.2013.11.039

Mikolašević, Ivana, et al. "Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients." Medical Hypotheses, vol. 82, no. 2, 2014, pp. 205-208. https://doi.org/10.1016/j.mehy.2013.11.039

Mikolašević, Ivana, Sanjin Rački, Luka. Zaputović, V. Lukenda, Sandra Milić and Lidija Orlić. "Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients." Medical Hypotheses 82, no. 2 (2014): 205-208. https://doi.org/10.1016/j.mehy.2013.11.039

Mikolašević, I., et al. (2014) 'Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients', Medical Hypotheses, 82(2), pp. 205-208. doi: 10.1016/j.mehy.2013.11.039

Mikolašević I, Rački S, Zaputović L, Lukenda V, Milić S, Orlić L. Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients. Medical Hypotheses [Internet]. 2014 February [cited 2024 December 19];82(2):205-208. doi: 10.1016/j.mehy.2013.11.039

I. Mikolašević, S. Rački, L. Zaputović, V. Lukenda, S. Milić and L. Orlić, "Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients", Medical Hypotheses, vol. 82, no. 2, pp. 205-208, February 2014. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:432619. [Accessed: 19 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients
AuthorIvana Mikolašević
AuthorSanjin Rački
AuthorLuka. Zaputović
AuthorV. Lukenda
AuthorSandra Milić
AuthorLidija Orlić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. Today it is believed that NAFLD is a hepatic manifestation of metabolic syndrome, and thus it is closely related to the cardiovascular morbidity and mortality. Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in patients with end-stage-renal disease (ESRD). NAFLD and ESRD share some important cardiometabolic risk factors and possible common pathophyisiological mechanisms, and are linked to an increased risk of incident CVD events. We hypothesize that the coexistence of these two conditions could lead to much faster progress of the aterogenic process. Furthermore, patients with ESRD who suffer from NAFLD have a much higher risk for the development of adverse CVD events. Given the high prevalence of NAFLD, and its tight association with other manifestations of the metabolic syndrome and thus cardiovascular complications, it is important to recognize and aggressively treat this condition in ESRD patients. To evaluate this hypothesis, we propose the use of non-invasive methods such as transient elastography (TE) (Fibroscan-CAP) for the detection and quantification of liver steatosis and fibrosis, as well as an abdominal ultrasound for detecting liver steatosis. We focus on their correlation with carotid intima-media thickness (IMT) and plaque as surrogate measures of increased cardiovascular risk in HD patients in order to investigate the association of NAFLD and increase risk of adverse CVD events. This evaluation will prove useful in assessing the risk in HD patients with NAFLD for increase CVD mortality.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionAccepted version
Journal titleMedical Hypotheses
Numberingvol. 82, no. 2, pp. 205-208
p-ISSN0306-9877
DOIhttps://doi.org/10.1016/j.mehy.2013.11.039
URN:NBNurn:nbn:hr:184:432619
Publication2014-02
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0306987713005689
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2022-09-20 09:46:23